Brean Murray Carret & Co. Maintains a 'Buy' on Achillion Pharmaceuticals (ACHN); Becoming Top Hec C Play

Brean Murray Carret & Co. maintains a 'Buy' on Achillion Pharmaceuticals (NASDAQ: ACHN) price target of $20.00.

Analyst, Brian Skorney, said, "We believe ACHN is positioned, post EASL abstracts, with the most compelling value proposition in the Hep C space. In ACH-1625, Achillion has the asset best positioned to compete with Gilead (Nasdaq: GILD)(Buy-rated) in a race to a once-daily, pan-genotyplic, interferon-free treatment regimen: a one size fits all treatment for all Hep C patients. We believe competitive data clearly indicates that a nuc is not necessary to eliminate interferon from the treatment regimen, provided the asset filling that role is very potent and exhibits a differentiated barrier to resistance. However, we believe it is important that the backbone agent has potent antiviral activity against fit resistant strains. We believe ACH-1625 is one of only a handful of assets that offer the hope of matching this profile."

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $10.47 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Freedom Broker Upgrades Taylor Devices, Inc. (TAYD) to Buy
• BMO Capital Starts D-Wave Quantum Inc. (QBTS) at Outperform
• Baird Starts Hubbell (HUBB) at Outperform